AxoGen Inc
NASDAQ:AXGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.67
15.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AxoGen Inc
AxoGen Inc
Current Portion of Long-Term Debt
AxoGen Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AxoGen Inc
NASDAQ:AXGN
|
Current Portion of Long-Term Debt
$6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Current Portion of Long-Term Debt
$2.2B
|
CAGR 3-Years
63%
|
CAGR 5-Years
11%
|
CAGR 10-Years
27%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Current Portion of Long-Term Debt
$1.7B
|
CAGR 3-Years
85%
|
CAGR 5-Years
5%
|
CAGR 10-Years
88%
|
|
|
Stryker Corp
NYSE:SYK
|
Current Portion of Long-Term Debt
$2.2B
|
CAGR 3-Years
361%
|
CAGR 5-Years
33%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Current Portion of Long-Term Debt
$1.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
23%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
AxoGen Inc
Glance View
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
See Also
What is AxoGen Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
6k
USD
Based on the financial report for Sep 30, 2024, AxoGen Inc's Current Portion of Long-Term Debt amounts to 6k USD.
You don't have any saved screeners yet
